ImmunityBio (IBRX) to Release Quarterly Earnings on Monday

Key Points

• Q1 2026 earnings: ImmunityBio will report results before the market opens on Monday, May 11, with analysts forecasting a ($0.08) EPS loss and about $43.07 million in revenue, and the company scheduling an earnings call for May 15 at 9:30 AM ET.
• Insider selling: Insiders have sold 275,000 shares worth roughly $2.93 million over the past 90 days (notably two director sales in February), although insiders still own about 69.48% of the company.
• Analyst sentiment & price outlook: IBRX trades near $7.51 with a $7.72 billion market cap, carries a consensus "Moderate Buy" rating and a $14.40 average price target, while analyst views range from Sell to Strong Buy.

ImmunityBio (NASDAQ:IBRX - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $43.0690 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. On average, analysts expect ImmunityBio to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ImmunityBio Price Performance

IBRX traded up $0.40 on Monday, hitting $7.51. 3,509,223 shares of the stock were exchanged, compared to its average volume of 32,021,395. ImmunityBio has a 12 month low of $1.83 and a 12 month high of $12.43. The business has a 50-day moving average of $8.13 and a two-hundred day moving average of $5.06. The firm has a market capitalization of $7.72 billion, a price-to-earnings ratio of -19.78 and a beta of 0.02.

Insider Buying and Selling

In related news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Barry J. Simon sold 165,000 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 275,000 shares of company stock worth $2,934,500 over the last 90 days. Company insiders own 69.48% of the company's stock.

Institutional Investors Weigh In On ImmunityBio

Several large investors have recently made changes to their positions in IBRX. Arax Advisory Partners boosted its position in shares of ImmunityBio by 36.5% during the 4th quarter. Arax Advisory Partners now owns 22,156 shares of the company's stock valued at $44,000 after acquiring an additional 5,925 shares during the last quarter. Voleon Capital Management LP bought a new stake in shares of ImmunityBio during the 3rd quarter valued at about $40,000. Cibc World Markets Corp bought a new stake in ImmunityBio in the 4th quarter worth approximately $39,000. EP Wealth Advisors LLC bought a new stake in ImmunityBio in the 4th quarter worth approximately $35,000. Finally, Engineers Gate Manager LP bought a new stake in ImmunityBio in the 2nd quarter worth approximately $35,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on IBRX shares. Piper Sandler reaffirmed an "overweight" rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ImmunityBio in a research note on Tuesday, April 14th. BTIG Research started coverage on ImmunityBio in a research note on Thursday, March 12th. They issued a "buy" rating and a $13.00 price objective for the company. The Goldman Sachs Group reaffirmed a "buy" rating on shares of ImmunityBio in a research note on Monday, February 23rd. Finally, HC Wainwright upped their price objective on ImmunityBio from $10.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $14.40.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.